Amprenavir Conference Data

Medical Advocates
Amprenavir (Agenerase)

Conference Citations

1st European HIV Drug Resistance Workshop
41st ICAAC

Amprenavir Main Page Main New/Newsworthy Home Page

Last Update: July 30, 2015
Pediatric data are in the Pediatric Data Page
Documents identified with this icon are in Portable Document Format (PDF) and require the Adobe Acrobat Reader

1st European HIV Drug Resistance Workshop

Distinct cross-resistance profiles of the new protease inhibitors (PI) Amprenavir, Lopinavir, and
Atazanavir in a panel of clinical samples
B. Schmidt^,T. Schnell ^,, G. Moschik, et al
Abstract

41st ICAAC

Impact of ABT 378/r on the Amprenavir (APV) Plasma Concentrations in HIV-Experienced
Patients Treated by the Association APV –ABT 378/r
Abstract

Variations in HIV-1 Gag p6 Contribute to the Amprenavir-Specific Protease I50V Resistance
Pathway
Abstract

In Vitro Model for Antiviral Activity for Amprenavir (APV)/Ritonavir (RTV)
Abstract

Risk of Amprenavir (APV) Rash in HIV Patients with Prior Exposure to Sulfonamides
Abstract

An Assessment of Plasma Amprenavir (APV) Pharmacokinetics (PK) Following Administration
of Two GW433908 (908) and Ritonavir (RTV) QD Regimens in Combination with Efavirenz (EFV)
in Healthy Adult Subjects (APV10009)
Abstract

Amprenavir Main Page Main New/Newsworthy Home Page

Amprenavir Conference Reports, Abstracts, and Posters